ñññð¾ð¹ñð¸ð²ð¾ñññ

Results 91 to 100 of about 5,871,720 (248)

Ticraḍ, gar usemres d wazal n yizamulen i d-mmalent

Ussnan
This contribution aims to describe the practice of tattooing in some Amazigh regions. It tries to list the different techniques, the actors plus the means used to succeed in this practice which has a high value in the society.
Ourida AISSOU
doaj

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau +9 more
wiley +1 more source

, 2012
Ivan Travkin
openalex +4 more sources

D. Seifried, N. Stark: Energiedienstleistungen

Technikfolgenabschätzung – Theorie und Praxis, 1994
TATuP editorial office
doaj +1 more source

Tixutert n tmezgunt deg uselmed/almad n tutlayt n tmaziɣt. Amedya: Asif n tisselbi i d-yettwasuɣlen seg taɛrabt.

Ussnan
Amagrad-a yewwi-d ɣef txutert n uselmed/almad n tutlayt tmaziɣt s umezgun, amedya tamezgunt n Tawfik El-Hakim yettwasuɣlen ilmend n yidles amaziɣ. Tazrawt-a treṣṣa ɣef yinefkan n tsastant i nga s udiwenni d yiselmaden akked temsirin i neḥḍer deg tneɣrit.
Hassiba Kherbouche, Mohammed Agaoua
doaj

, 2020
Ð¡Ð ̧Ð ⁄ ÐμÐ ⁄ Ð ⁄ Ð¡Ð ̧Ð ⁄ ÐμÐ ⁄ Ð ⁄ Ð ⁄ Ð
openalex

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias +12 more
wiley +1 more source

computer science
chemistry
mathematics

environmental chemistry
medicine
environmental science

combinatorics
internal medicine
crystal structure